{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:25:39Z","timestamp":1783470339853,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,28]],"date-time":"2018-04-28T00:00:00Z","timestamp":1524873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.alit.2018.03.008","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T19:36:30Z","timestamp":1526499390000},"page":"301-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases"],"prefix":"10.1016","volume":"67","author":[{"given":"Hendrik","family":"Nolte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2018.03.008_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the world health organization, GA(2)LEN and AllerGen)","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2018.03.008_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1365-2222.2001.00999.x","article-title":"Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers","volume":"31","author":"Bagnasco","year":"2001","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2018.03.008_bib3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0091-6749(97)70203-3","article-title":"Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings","volume":"100","author":"Bagnasco","year":"1997","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib4","doi-asserted-by":"crossref","first-page":"623474","DOI":"10.1155\/2012\/623474","article-title":"Induction of tolerance via the sublingual route: mechanisms and applications","volume":"2012","author":"Moingeon","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib5","series-title":"Global Strategy for Asthma Management and Prevention","author":"Global Initiative for Asthma (GINA)","year":"2017"},{"key":"10.1016\/j.alit.2018.03.008_bib6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.anai.2016.12.009","article-title":"Sublingual immunotherapy. A focused allergen immunotherapy practice parameter update","volume":"118","author":"Greenhawt","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib7","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.anai.2014.02.006","article-title":"Diagnosis and treatment of nasal and ocular allergies: the allergies, immunotherapy, and rhinoconjunctivitiS (AIRS) surveys","volume":"112","author":"Blaiss","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/all.12838","article-title":"Medical care and treatment of allergic rhinitis: a population-based cohort study based on routine healthcare utilization data","volume":"71","author":"Schmitt","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2018.03.008_bib9","article-title":"House dust mite control measures for asthma","author":"Gotzsche","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.alit.2018.03.008_bib10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2500\/aap.2014.35.3766","article-title":"Current allergic rhinitis experiences survey (cares): consumers' awareness, attitudes and practices","volume":"35","author":"Fromer","year":"2014","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.alit.2018.03.008_bib11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1586\/1744666X.2015.1062726","article-title":"Allergen immunotherapy: what's new, what's next?","volume":"11","author":"Nelson","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib12","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaci.2011.12.973","article-title":"SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial","volume":"129","author":"Durham","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaci.2017.06.014","article-title":"Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy","volume":"141","author":"Valovirta","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib14","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human use (CHMP). Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases EMEA\/CHMP\/EWP\/18504\/2006."},{"key":"10.1016\/j.alit.2018.03.008_bib15","series-title":"Release of Guidance Document: Regulatory Framework for Unauthorized New Allergenic Products of Biological Origin Used for the Diagnosis or Treatment of Allergic Diseases","author":"Health Canada","year":"2012"},{"key":"10.1016\/j.alit.2018.03.008_bib16","series-title":"Allergic Rhinitis: Developing Drug Products for Treatment Guidance for Industry","author":"Food and Drug Administration (CDER)","year":"2016"},{"key":"10.1016\/j.alit.2018.03.008_bib17","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jaci.2013.11.012","article-title":"Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis","volume":"133","author":"Bergmann","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaci.2010.11.034","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents","volume":"127","author":"Blaiss","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaci.2008.10.044","article-title":"Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy","volume":"123","author":"Bufe","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib20","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jaci.2012.08.032","article-title":"Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE","volume":"130","author":"Cox","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib21","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.jaci.2013.03.019","article-title":"Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults","volume":"131","author":"Creticos","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaci.2006.05.003","article-title":"Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis","volume":"118","author":"Dahl","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1398-9995.2005.00949.x","article-title":"Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis","volume":"61","author":"Dahl","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2018.03.008_bib24","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jaci.2007.07.046","article-title":"Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis","volume":"120","author":"Didier","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaci.2005.12.1358","article-title":"Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis","volume":"117","author":"Durham","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaip.2015.11.004","article-title":"Sequential treatment initiation with timothy grass and ragweed sublingual immunotherapy tablets followed by simultaneous treatment is well tolerated","volume":"4","author":"Maloney","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2018.03.008_bib27","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.anai.2013.11.018","article-title":"Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial","volume":"112","author":"Maloney","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib28","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaci.2014.03.019","article-title":"Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Mosbech","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2010.11.035","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults","volume":"127","author":"Nelson","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.anai.2013.03.013","article-title":"Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults","volume":"110","author":"Nolte","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib31","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1001\/jama.2016.3964","article-title":"Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial","volume":"315","author":"Virchow","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.alit.2018.03.008_bib32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaci.2008.10.009","article-title":"Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis","volume":"123","author":"Wahn","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib33","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jaci.2013.10.041","article-title":"Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis","volume":"133","author":"Creticos","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib34","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.jaci.2016.06.044","article-title":"Efficacy of house dust mite SLIT-tablet in North American adolescents and adults in a randomized, placebo-controlled trial","volume":"138","author":"Nolte","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib35","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.jaci.2016.09.043","article-title":"Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite\u2013induced allergic rhinitis","volume":"139","author":"Okubo","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib36","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jaci.2015.06.036","article-title":"Effective treatment of house dust mite\u2013induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized double-blind, placebo-controlled phase III trial","volume":"137","author":"Demoly","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib37","series-title":"Grastek (Timothy Grass Pollen Allergen Extract Tablet for Sublingual Use). Full\u00a0Prescribing Information","year":"2014"},{"key":"10.1016\/j.alit.2018.03.008_bib38","series-title":"Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract Tablet for Sublingual Use). Full Prescribing Information","year":"2014"},{"key":"10.1016\/j.alit.2018.03.008_bib39","series-title":"Ragwitek (Short Ragweed Pollen Allergen Extract Tablet for Sublingual Use). Full Prescribing Information","year":"2014"},{"key":"10.1016\/j.alit.2018.03.008_bib40","series-title":"ODACTRA\u2122 House Dust Mite (Dermatophagoides Farinae and Dermatophagoides Pteronyssinus) Allergen Extract Tablet for Sublingual Use","year":"2017"},{"key":"10.1016\/j.alit.2018.03.008_bib41","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.jaci.2014.12.1911","article-title":"Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber","volume":"135","author":"Nolte","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jaci.2009.06.006","article-title":"Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber","volume":"124","author":"Horak","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib43","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/all.12074","article-title":"Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects","volume":"68","author":"Nelson","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2018.03.008_bib44","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/00325481.2017.1302306","article-title":"A\u00a0practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice","volume":"129","author":"Bernstein","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.alit.2018.03.008_bib45","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/all.12373","article-title":"Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure","volume":"69","author":"Durham","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2018.03.008_bib46","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jaci.2013.09.004","article-title":"An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies","volume":"132","author":"Calderon","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib47","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.anai.2016.07.004","article-title":"Major allergen content consistency of SQ house dust mite SLIT-tablets and relevance across geographic regions","volume":"117","author":"Nolte","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib48","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaip.2014.09.018","article-title":"Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy","volume":"3","author":"Nelson","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2018.03.008_bib49","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jaci.2015.12.1298","article-title":"Sublingual or subcutaneous immunotherapy for allergic rhinitis","volume":"137","author":"Durham","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib50","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/alr.21349","article-title":"The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: provider practices and beliefs about allergen immunotherapy","volume":"4","author":"Leatherman","year":"2014","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.alit.2018.03.008_bib51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11882-017-0687-0","article-title":"Allergen immunotherapy clinical trial outcomes and design: working toward harmonization of methods and principles","volume":"17","author":"Nelson","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.alit.2018.03.008_bib52","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.amjmed.2003.10.030","article-title":"Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis","volume":"116","author":"Wilson","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.alit.2018.03.008_bib53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.anai.2009.11.020","article-title":"Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class","volume":"104","author":"Benninger","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1741-7015-12-71","article-title":"A\u00a0meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis","volume":"12","author":"Devillier","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.alit.2018.03.008_bib55","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaci.2016.04.061","article-title":"Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: pooled analyses","volume":"138","author":"Durham","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaip.2014.01.004","article-title":"AAAAI\/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions","volume":"2","author":"Epstein","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2018.03.008_bib57","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.anai.2016.02.001","article-title":"Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: national surveillance study on allergen immunotherapy (2008\u20132013)","volume":"116","author":"Epstein","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib58","first-page":"241","article-title":"Compliance with an allergen immunotherapy regime","volume":"74","author":"Tinkelman","year":"1995","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaip.2016.08.017","article-title":"Epinephrine use in clinical trials of sublingual immunotherapy tablets","volume":"5","author":"Nolte","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2018.03.008_bib60","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/alr.21037","article-title":"A\u00a0comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy","volume":"2","author":"Hsu","year":"2012","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.alit.2018.03.008_bib61","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ACI.0000000000000084","article-title":"Allergy immunotherapy: what is the evidence for cost saving?","volume":"14","author":"Hankin","year":"2014","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib62","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jaci.2007.10.026","article-title":"Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs","volume":"121","author":"Hankin","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib63","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1081-1206(10)62370-8","article-title":"Factors affecting compliance with allergen immunotherapy at a military medical center","volume":"88","author":"More","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib64","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/0091-6749(93)90192-I","article-title":"Determinants of patient compliance with allergen immunotherapy","volume":"91","author":"Cohn","year":"1993","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib65","first-page":"480","article-title":"Compliance with allergen immunotherapy","volume":"70","author":"Lower","year":"1993","journal-title":"Ann Allergy"},{"key":"10.1016\/j.alit.2018.03.008_bib66","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13601-015-0057-8","article-title":"Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score","volume":"5","author":"Didier","year":"2015","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.alit.2018.03.008_bib67","first-page":"A7","article-title":"Occurrence and duration of local adverse reactions is similar for the ragweed (MK-3641), grass (MK-7243), and house dust mite (MK-8237) sublingual immunotherapy tablets and consistent with an immediate IgE-mediated reaction","volume":"113","author":"Nelson","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib68","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2016.05.014","article-title":"Coseasonal initiation of allergen immunotherapy: a systematic review","volume":"4","author":"Creticos","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2018.03.008_bib69","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jaci.2015.04.045","article-title":"Randomised controlled trial of house dust mite allergen oral immunotherapy in early childhood","volume":"136","author":"Zolkipli","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2018.03.008_bib70","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2012.09.015","article-title":"Learning early about peanut allergy (LEAP) study team. Identifying infants at high risk of peanut allergy: the learning early about peanut allergy (LEAP) screening study","volume":"131","author":"Du Toit","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893018300480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893018300480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:08:20Z","timestamp":1761156500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893018300480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1323893018300480"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2018.03.008","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2018.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Japanese Society of Allergology. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}